| 4 min read
Why 2023 is the year that antibody manufacturers should embrace CRISPR gene editing.
Without the right predictive analytical methods and tools, the cell and gene therapy field will be held back
China drafts new gene-editing regulations – but concerns over their enforcement remain.
How will the storm whipped up by He Juinkai’s flagrant disregard for medical ethics affect the wider ambitions of the gene-editing field?
Harvard Medical School’s Richard Sherwood digs into the potential and pitfalls of gene editing technology.
Cutting-edge imaging, predictive modeling and gene therapy combine for a new direction in neurodegenerative disease research
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.
You will benefit from:
Express Insight into Bladder Cancer
Changing the Leopard’s Spots
Making It (Im)personal